21 completed. 21 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 21 | Completed 21 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer Ondansetron 8mg, Aprepitant 125 mg - Thyroid Cancer | Phase 4 | Completed | The First Affiliated Hospital of Zhengzhou University | 600 | 2024-07-01 | 2025-01-22 |
| Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 LCZ 696, Placebo, Para-aminohippurate - Heart Failure | Phase 4 | Completed | Yale University | 46 | 2021-05-27 | 2026-10-27 |
| Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 103 | 2019-09-09 | 2025-01-16 |
| Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting Aprepitant and Dexamethasone, Mirtazapine and Dexamethasone, Dexamethasone - Nausea and Vomiting, Postoperative | Phase 4 | Completed | Ain Shams University | 90 | 2019-07-15 | 2020-01-03 |
| Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia - Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy | Phase 4 | Completed | Stony Brook University | 83 | 2017-08-28 | 2024-02-14 |
| Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone ramosetron, aprepitant, dexamethasone, palonosetron, aprepitant, dexamethasone - Cancer, Tumors | Phase 4 | Completed | Kangdong Sacred Heart Hospital | 292 | 2015-08-19 | 2018-05-11 |
| Neurokinin Receptor Antagonist Associated to Ondansetron in PONV Aprepitant - Postoperative Nausea and Vomiting | Phase 4 | Completed | Instituto do Cancer do Estado de São Paulo | 90 | 2015-02-01 | 2015-08-25 |
| A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) Aprepitant, Aprepitant Placebo, Ondansetron - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 494 | 2012-12-12 | 2018-09-25 |
| The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting Aprepitant, placebo - Postoperative Nausea and Vomiting | Phase 4 | Completed | Yonsei University | 125 | 2012-06-01 | 2013-07-11 |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting fosaprepitant, aprepitant, Oral Placebo - Ovarian Cancer, Uterine Cancer | Phase 4 | Completed | Gynecologic Oncology Associates | 20 | 2011-09-01 | 2017-03-28 |
| Prevention of Nausea and Vomiting in Patients After Surgery Dexamethasone and aprepitant, Dexamethasone and ondansetron - Postoperative Nausea and Vomiting | Phase 4 | Completed | Yeditepe University Hospital | 67 | 2011-07-01 | 2013-12-27 |
| Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. Aprepitant - Breast Cancer | Phase 4 | Completed | Spanish Breast Cancer Research Group | 212 | 2011-05-01 | 2023-03-07 |
| Effects of Substance P Antagonists on Adrenal Secretion aprepitant/placebo - Healthy Volunteers | Phase 4 | Completed | University Hospital, Rouen | 20 | 2009-06-01 | 2012-02-16 |
| Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients Aprepitant, Dexamethasone, Ondansetron, Aprepitant, Dexamethasone, Placebo - Postoperative Nausea and Vomiting | Phase 4 | Completed | Scott and White Hospital & Clinic | 100 | 2008-07-01 | 2013-12-19 |
| Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery Aprepitant plus Ondansetron, Ondansetron plus placebo - Postoperative Nausea and Vomiting | Phase 4 | Completed | University of Pittsburgh | 150 | 2008-06-01 | 2013-02-06 |
| Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy Aprepitant + Dexamethasone, Ondansetron + Dexamethasone - Postoperative Nausea and Vomiting | Phase 4 | Completed | Duke University | 115 | 2007-09-01 | 2017-03-13 |
| Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting Aprepitant, Ondansetron, Promethazine - Postoperative Nausea and Vomiting (PONV), Nausea | Phase 4 | Completed | Sergio Bergese | 122 | 2007-06-01 | 2013-12-03 |
| AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Aprepitant, Palonosetron, Granisetron - Leukemia, Lymphoma | Phase 4 | Completed | PETHEMA Foundation | 196 | 2006-11-01 | 2009-09-18 |
| Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 477 | 2004-01-13 | 2017-04-24 |
| Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea Standard PO (Zofran + Dexamethason), Aprepitant (MK-869) + Standard PO - Nausea, Vomiting | Phase 4 | Completed | Loyola University | 181 | 2003-08-01 | 2018-07-27 |
Showing 20 of 21. Sign in to see all of them.
Vomiting (11) · Nausea (8) · Postoperative Nausea and Vomiting (8) · Breast Neoplasms (2) · Neoplasms (2) · Heart Failure (1) · Leukemia (1) · Lymphoma (1) · Ovarian Neoplasms (1) · Thyroid Neoplasms (1) · Uterine Neoplasms (1)
Merck Sharp & Dohme LLC (4) · Ain Shams University (1) · Duke University (1) · Gynecologic Oncology Associates (1) · Instituto do Cancer do Estado de São Paulo (1) · Kangdong Sacred Heart Hospital (1) · Loyola University (1) · PETHEMA Foundation (1) · Scott and White Hospital & Clinic (1) · Sergio Bergese (1) · Spanish Breast Cancer Research Group (1) · Stony Brook University (1) · The First Affiliated Hospital of Zhengzhou University (1) · University Hospital, Rouen (1) · University of Pittsburgh (1)
United States (8) · South Korea (2) · Spain (2) · Brazil (1) · China (1) · Egypt (1) · France (1) · Greece (1) · Hungary (1) · Lithuania (1) · Netherlands (1) · Peru (1) · Poland (1) · Russia (1) · Turkey (Türkiye) (1)
Ashraf S Habib, MBBCH, FRCA (1) · Detao Yin, M.D. (1) · Jin-Hyoung Kang, Ph.D (1) · John P Micha, MD (1) · Jung Hye Kwon, PhD (1) · Konstantinos Spaniolas, MD (1) · Manuel C Vallejo, MD (1) · Nancy J. Brown, MD (1) · Patrick Stiff, MD (1) · Sergio D Bergese, M.D. (1)
PMID 21081776, PMID 25220550, PMID 26694939, PMID 26994459, PMID 27826874, PMID 32471973, PMID 33528788, PMID 35535050, PMID 39655741
2008 (1), 2018 (1)